Vol. 25 - Num. 99
aPediatra. CS Guanarteme. Las Palmas de Gran Canaria. España. Miembro del Comité Asesor de Vacunas de la Asociación Española de Pediatría.
bServicio de Pediatría. Hospital Clínico Universitario de Santiago de Compostela. España. Miembro del Comité Asesor de Vacunas de la Asociación Española de Pediatría.
Correspondence: A Montesdeoca. E-mail: firstname.lastname@example.org
Reference of this article: Montesdeoca Melián A, Rivero Calle I. Comment by the Advisory Committee on Vaccines of the Spanish Association of Paediatrics on Evidences in Paediatrics about nirsevimab . Rev Pediatr Aten Primaria. 2023;25:309-12. https://doi.org/10.60147/978f3462
Published in Internet: 26-07-2023 - Visits: 2792
Bronchiolitis continues to be a major health problem in Spain, as it generates thousands of consultations in primary care every year, a backlog in paediatric hospitalisation and intensive care wards, and millions in costs to the National Health System. Most of those who require hospital admission are healthy infants, without any known risk factor. The very high incidence of the disease and the absence of a specific treatment means that paediatricians are impassive in the face of this annual epidemic, unable to offer our patients either a preventive or therapeutic option. In November 2022, the European Medicines Agency granted marketing authorisation for a monoclonal antibody specific against respiratory syncytial virus (RSV) F protein, following results from initial trials in more than 3,000 infants that demonstrated greater than 75% efficacy in preventing RSV hospitalisations. Preliminary results from the HARMONIE study, conducted in over 8000 individuals, were reported in May 2023, representing the first real-life experience with the use of nirsevimab and showing greater than 80% efficacy in preventing hospitalisations for bronchiolitis. This text presents the arguments of the Vaccine Advisory Committee of the Spanish Association of Paediatrics to support the recommendation made by this group for its routine use in newborns and infants under 6 months of age in Spain.
Keywords● Bronchiolitis ● Nirsevimab ● Respiratory syncytial virus
Este artículo se publica simultáneamente con la revista electrónica Evidencias en Pediatría (www.evidenciasenpediatria.es).
This article has no comments yet.